

# Robert Toto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2170097/publications.pdf>

Version: 2024-02-01

33  
papers

3,421  
citations

471509

17  
h-index

477307

29  
g-index

33  
all docs

33  
docs citations

33  
times ranked

4115  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2019-2032.	27.0	2,110
2	The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1083-1093.	6.1	222
3	Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. <i>Hypertension</i> , 2015, 65, 257-263.	2.7	169
4	Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized <scp>MARBINA</scp>â€œ<scp>T2D</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1610-1619.	4.4	119
5	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2352-2361.	6.1	88
6	Efficacy and Tolerability of Losartan in Hypertensive Patients With Renal Impairment. <i>Hypertension</i> , 1998, 31, 684-691.	2.7	85
7	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease. <i>Annals of Internal Medicine</i> , 2017, 167, 375.	3.9	78
8	Accrual to Clinical Trials (ACT): A Clinical and Translational Science Award Consortium Network. <i>JAMIA Open</i> , 2018, 1, 147-152.	2.0	78
9	BP Control and Long-Term Risk of ESRD and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 671-677.	6.1	71
10	Angiotensin II Subtype 1 Receptor Blockers and Renal Function. <i>Archives of Internal Medicine</i> , 2001, 161, 1492.	3.8	53
11	Effect of Low Versus High Dialysate Sodium Concentration on Blood Pressure and Endothelial-Derived Vasoregulators During Hemodialysis: A Randomized Crossover Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 464-473.	1.9	49
12	Dual Blockade of the Renin-Angiotensin-Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. <i>American Journal of Hypertension</i> , 2009, 22, 1032-1040.	2.0	46
13	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	8.6	44
14	Rationale for Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor Treatment and End-Organ Protection in Patients with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2008, 28, 372-380.	3.1	31
15	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 758-768.	1.8	29
16	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	6.3	28
17	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 749-753.	4.4	19
18	The effects of weight change on glomerular filtration rate. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1870-1877.	0.7	18

#	ARTICLE	IF	CITATIONS
19	Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2016, 117, 656-663.	1.6	18
20	Effect of Intensive Blood Pressure Control on Aortic Stiffness in the SPRINT-HEART. <i>Hypertension</i> , 2021, 77, 1571-1580.	2.7	17
21	Scale-up of the Accrual to Clinical Trials (ACT) network across the Clinical and Translational Science Award Consortium: a mixed-methods evaluation of the first 18 months. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 515-528.	0.6	9
22	Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes. <i>Translational Research</i> , 2020, 222, 17-27.	5.0	8
23	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Drugs in R and D</i> , 2017, 17, 441-448.	2.2	6
24	Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2019, 9, 316-325.	1.9	6
25	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 226-236.	2.9	6
26	Molecular Signatures of Diabetic Kidney Disease Hiding in a Patient with Hypertension-Related Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 594-601.	4.5	6
27	Comparison of exposure response relationship of atrasentan between North American and Asian populations. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 545-552.	4.4	4
28	A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 469-478.	6.1	2
29	FC 063DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	1
30	Accounting for quality improvement during the conduct of embedded pragmatic clinical trials within healthcare systems: NIH Collaboratory case studies. <i>Healthcare</i> , 2021, 8, 100432.	1.3	1
31	SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
32	The FIDELIO Study Podcast. <i>Diabetes Therapy</i> , 2022, , 1.	2.5	0
33	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0